FDA proposes mandatory GRAS notification regime

The US Food and Drug Administration has proposed converting its voluntary notification system for Generally Recognized as Safe substances into a mandatory programme covering certain human and animal food uses.

Under the proposed rule, a person introducing a substance into interstate commerce under the GRAS provision would generally have to notify FDA of the basis for concluding that the substance is safe under its intended conditions of use, unless one of the specified exceptions applies.

The proposal reaches beyond conventional ingredients. FDA’s definition for the rule includes substances added indirectly to food, including some arising from food packaging, widening its potential relevance across ingredient development, formulation, processing aids, and food-contact materials.

The regulatory distinction is important: mandatory notification would not turn GRAS into a conventional premarket approval system. FDA states explicitly that the proposed programme would remain different from food-additive approval and that a company could, under the proposal, introduce a purportedly GRAS substance before filing its notice.

Independent conclusions would become more visible

Under the existing framework, companies may submit a GRAS notice to FDA but are not generally required to do so. A business can reach an independent conclusion that a substance is GRAS under specified conditions and market it without placing that conclusion into the agency’s notification programme.

FDA argues that the voluntary structure creates information gaps because it does not always know which substances are entering the food supply on the basis of independent GRAS conclusions. The proposed rule is intended to give the agency and the public greater visibility of those uses and the scientific evidence supporting them.

For ingredient manufacturers and food producers, that would make regulatory documentation a more formal part of commercialisation. Safety evidence, intended use, conditions of use, and other information supporting the GRAS conclusion would have to be assembled for submission where the mandatory requirement applies.

That work would have to sit alongside product development rather than being treated only as an internal legal file. A novel ingredient may move through application trials, formulation work, shelf-life studies, customer qualification, scale-up, and supply agreements before commercial launch. A mandatory notification requirement adds another defined workstream whose evidence has to remain consistent with the intended use being sold to customers.

The rule also creates exceptions. An existing FDA no-questions letter covering the substance under its intended conditions of use is among the circumstances in which another GRAS notice would not be required. Other exemptions and pathways are set out in the proposed amendments, making the scope more complicated than a blanket requirement to refile every substance already in the market.

Existing substances get a proposed transition route

FDA is proposing a time-limited streamlined pathway for qualifying substances that were already in interstate commerce under an independent GRAS conclusion before a final rule became effective. Companies using that option would submit specified information about the substance and its conditions of use instead of immediately filing a full GRAS notice.

The streamlined option would be available for one year from the effective date of a final rule. FDA says the mechanism is intended to help it build a more comprehensive catalogue of existing GRAS uses without overwhelming the agency with full notices for every substance already being marketed.

The proposal would still create recurring work for new uses that would otherwise have relied on independent GRAS conclusions. FDA’s preliminary economic analysis estimates annualised industry and agency costs of approximately $10.5 million under its central 3% discount-rate calculation, with a range reflecting uncertainty around the number and complexity of submissions.

The agency also concludes that the proposed rule would have a significant economic impact on a substantial number of small entities, based on its estimate that compliance effects could exceed 3% of annual revenue for affected small businesses. FDA is therefore requesting comments on alternatives that could reduce regulatory burden while still improving transparency and safety oversight.

International suppliers would not be insulated from the change where they introduce substances into the US market. FDA’s own cost analysis anticipates translation costs for manufacturers in non-English-speaking countries, illustrating the additional documentation work that could follow for overseas ingredient businesses selling into US food production.

None of those requirements takes effect merely because the proposal has been published. Comments are open until 9 December 2026. FDA proposes that a final rule would take effect 60 days after publication, with the principal mandatory-notification provisions carrying an 18-month compliance period after that effective date.

That timeline gives manufacturers a reason to audit their ingredient and food-contact portfolios before the rule is final without assuming that the current wording will survive unchanged. Companies can establish which uses depend on independently reached GRAS conclusions, which already have FDA no-questions letters or another relevant status, and where supporting safety evidence sits within the organisation or supply chain.

The proposal leaves the fundamental GRAS concept in place while changing how quietly it can be used. If finalised substantially as written, independent safety conclusions would remain possible, but many would move from private company files into a mandatory FDA notification and public-information framework.